Generex Biotech Cash Flow - Quarterly (OTCMKTS:GNBT)

Add to My Stocks
$2.1 $0 (0%) GNBT stock closing price Sep 21, 2018 (Closing)

The financial analysis of GNBT requires an investor to check the cash flows for Generex Biotech. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Generex Biotech profits and Generex Biotech debt. Generex Biotech stock analysis shows positive net income cash flow of $21.12M till 2018 Q3. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Generex Biotech has a negative cash and cash equivalents change of $-1.31M.

View and download details of Generex Biotech cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Aug - Jul2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow---13.38M14.48M14.33M---
Net Increase (Decrease) in Assets Liabilities-------1.1M-
Cash From (used in) Discontinued Operations---------
Other Adjustments Net-23.35M-18.77M-28.29M61.28M48.74M--0.77M1.08M-0.89M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.01M-0.01M-------
Acquisition Disposition of Subsidiaires---------
Increase (Decrease) in Investments-----4M----
Other Cash Inflow (Outflow) from Investment Activities------0.42M---
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares---3.05M3.05M----
Issuance (Repayment) of Debt Securities---------
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities---------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----0.01M----0.01M-0.01M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year--3.26M1.7M-2.79M13.88M14.19M17.23M
Cash & Equivalents at Year End1.56M2.04M2.33M2.87M-----
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Generex Biotech stock price history and Generex Biotech stock comparison chart inevitably reflect its cash flow situation.

  • Generex Biotech has cash of $1.56M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Generex Biotech stock price.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Generex Biotech lost $-1.67M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-0.01M for GNBT till last quarter 2018 Q3 report.
  • Cash flow from financing activities shows the flow of cash between Generex Biotech and its owners and creditors and was $- till 2018 Q3. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Generex Biotech Cash Flow

FCF margin

Quarterly Cash Flow Statements For Generex Biotechnology Corporation Peers

Aoxing Pharma cash flow, COTINGA PHARMA cash flow, MannKind cash flow, Novo Nordisk cash flow, Acerus Pharma cash flow